John Luk studied Education and training at the University of Hong Kong, Karolinska (Stockholm) and Harvard (Boston), he also taught as academic professor for 18 years in the US, HK and Singapore. John was identified and patented CDH17 at HKU (Global License Arbele). In 2011, he moved to drug industry at senior leader position in Roche China and senior director in Johnson & Johnson Medical China to lead drug discovery and development programs in oncology, immunology and hepatitis. John was a former honorary professorship at leading institutions in HK, China and Asia; visiting associate professor at Harvard; established strong scientific, clinical and industrial networks globally.
Current role